


Title	Estrogen Induces Mammary Ductal Dysplasia via the Upregulation of Myc Expression in a DNA-Repair-Deficient Condition
Author(s)	Itou, Junji; Takahashi, Rei; Sasanuma, Hiroyuki; Tsuda, Masataka; Morimoto, Suguru; Matsumoto, Yoshiaki; Ishii, Tomoko; Sato, Fumiaki; Takeda, Shunichi; Toi, Masakazu
Citation	iScience (2020), 23(2)
Issue Date	2020-02-21
URL	http://hdl.handle.net/2433/245443
Right	© 2020 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Type	Journal Article
Textversion	publisher

Article

Estrogen Induces Mammary Ductal Dysplasia via the Upregulation of Myc Expression in a DNA-Repair-Deficient Condition



Junji Itou, Rei Takahashi, Hiroyuki Sasanuma, ..., Fumiaki Sato, Shunichi Takeda, Masakazu Toi

junji-itou@umin.ac.jp

HIGHLIGHTS

Excess amount of estrogen administration in scid mice induces mammary ductal dysplasia

E2-induced Myc expression is one of the causes of dysplasia formation

Progesterone and isoflavones have a potential to prevent E2-induced dysplasia

Itou et al., iScience 23, 100821
February 21, 2020 © 2020 The Author(s).
<https://doi.org/10.1016/j.isci.2020.100821>

Article

Estrogen Induces Mammary Ductal Dysplasia via the Upregulation of Myc Expression in a DNA-Repair-Deficient Condition

Junji Itou,^{1,2,7,*} Rei Takahashi,³ Hiroyuki Sasanuma,⁴ Masataka Tsuda,^{4,5} Suguru Morimoto,⁴ Yoshiaki Matsumoto,² Tomoko Ishii,² Fumiaki Sato,^{2,6} Shunichi Takeda,⁴ and Masakazu Toi²

SUMMARY

Mammary ductal dysplasia is a phenotype observed in precancerous lesions and early-stage breast cancer. However, the mechanism of dysplasia formation remains elusive. Here we show, by establishing a novel dysplasia model system, that estrogen, a female hormone, has the potential to cause mammary ductal dysplasia. We injected estradiol (E2), the most active form of estrogen, daily into scid mice with a defect in non-homologous end joining repair and observed dysplasia formation with cell proliferation at day 30. The protooncogene *Myc* is a downstream target of estrogen signaling, and we found that its expression is augmented in mammary epithelial cells in this dysplasia model. Treatment with a *Myc* inhibitor reduced E2-induced dysplasia formation. Moreover, we found that isoflavones inhibited E2-induced dysplasia formation. Our dysplasia model system provides insights into the mechanistic understanding of breast tumorigenesis and the development of breast cancer prevention.

INTRODUCTION

During breast tumorigenesis, mammary ductal dysplasia is observed in precancerous lesions and early-stage breast cancers. Mammary ductal dysplasia exhibits a loss of the biphasic mammary epithelial and myoepithelial pattern, an abnormal nucleus, epithelial cell expansion, a disruption in the myoepithelial cell layer, and/or mammary epithelial cell invasion to fibrous stroma, whereas a normal mammary duct maintains cell polarization, the biphasic pattern, and the smooth luminal surface of the mammary epithelial cell layer. Given that dysplasia can progress to malignant neoplasms (Arpino et al., 2005; Cichon et al., 2010; Sgroi, 2010), elucidating the mechanism of dysplasia formation will contribute to the prevention of breast tumorigenesis.

Previous studies have established various breast cancer mouse models by genetic engineering. For example, the mammary gland-specific expression of *c-neu* (*Her2/ErbB2*), *polyoma middle T* antigen, and *Wnt-1* causes breast cancer (Guy et al., 1992; Li et al., 2000; Muller et al., 1988). Mice with a mutation in *Tp53*, a tumor suppressor gene, also developed breast cancer (Kuperwasser et al., 2000). Although these models have provided knowledge about breast cancer, particularly at an advanced stage, they have not been primarily used for studies on mammary ductal dysplasia observed in precancerous lesions and early-stage breast cancers. Previous dysplasia studies in mice used radiation in *ataxia telangiectasia mutated* heterozygous mice (Weil et al., 2001) and the overexpression of constitutively activated Smoothed receptor (Morales et al., 2007) and of the oncogene *nuclear receptor-binding SET domain protein 3* (Turner-Ivey et al., 2017). Because studies using genetically engineered mice have been designed to examine phenotypes specifically caused by the functions of their target genes and these studies could not provide knowledge about the relationships between the factors involved, these models are not suitable to elucidate the molecular mechanism by which mammary ductal dysplasia is naturally formed. To understand such a mechanism of dysplasia formation, a mouse model that forms dysplasia by physiological factor(s) and facilitates the mechanistic understanding of dysplasia formation is required.

Estrogen, a female hormone, promotes the development of the normal mammary duct and the proliferation of breast cancer (reviews Deroo and Korach, 2006; Heldring et al., 2007; Liang and Shang, 2013; Manavathi et al., 2013). There are a number of studies on the function of estrogen in breast cancer (reviews Burns and Korach, 2012; Deroo and Korach, 2006; Liang and Shang, 2013; Manavathi et al., 2013; Siersbæk et al., 2018). Although estrogen is thought to be involved in breast tumorigenesis in epidemiologic studies (Dall

¹Laboratory of Molecular Life Science, Institute for Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe (FBRI), 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan

²Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

³Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, 97-1 Kodo, Kyotanabe 610-0395, Japan

⁴Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Kyoto 606-8501, Japan

⁵Program of Mathematical and Life Science, Graduate School of Integrated Sciences for Life, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima 739-8526, Japan

⁶Department of Breast Surgery, Kansai Electric Power Hospital & Kansai Electric Power Medical Research Institute, 2-1-7 Fukushima, Fukushima-ku, Osaka 553-0003, Japan

⁷Lead Contact

*Correspondence: junji-itou@umin.ac.jp

<https://doi.org/10.1016/j.isci.2020.100821>






Figure 1. Estrogen Administration Induces Mammary Ductal Dysplasia in scid Mice

(A) DNA double-strand breaks were detected in MCF-7 cells. *PRKDC* was knocked down. Gamma-H2AX was immunostained. Numbers of gH2AX foci per cell were graphed (jitter plot). Black dots indicate mean values. Data were obtained from 2 or 3 independent experiments (total 200–520 cells in each group, U Mann-Whitney test).

(B) Messenger RNA levels of *GREB1*, *TFF1*, and *MYC* were quantified ($n = 3$ experiments, one-way ANOVA followed by Tukey's test). Cells were treated with or without E2 for 6 h.

(C) Gamma-H2AX-positive mammary epithelial cells were detected and quantified at 6, 9, and 12 h after E2 administration ($n = 3$ mice in wild-type [WT] + E2 0 h, 6 h, 9 h, 12 h and scid + E2 0 h, 6 h, 9 h, 12 h; $n = 4$ mice in scid + E2 + fulvestrant 6 h, one-way ANOVA followed by Tukey's test).

Figure 1. Continued

(D) Typical images of H&E staining are shown. Daily injection of E2 was performed for 30 days. The table shows ratios of dysplasia ($n = 6$ mice [one image from each mouse, total six images], WT + E2 4.49%, scid + PBS 2.07% [$p = 0.274$, versus WT + E2], and scid + E2 16.58% [$p = 0.002$, versus WT + E2], U Mann-Whitney test).

(E) Typical immunostaining images of CK5 are shown. The table shows ratios of disruption ($n = 6$ mice [one image from each mouse, total six images], WT + E2 0.92%, scid + PBS 0.52% [$p = 1.00$, versus WT + E2], and scid + E2 5.23% [$p = 0.041$, versus WT + E2], U Mann-Whitney test).

(F) Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion were quantified ($n = 10$ mice in WT + E2, scid + PBS and scid + E2 groups, $n = 6$ mice in scid + E2+Fulv. group, one-way ANOVA followed by Tukey's test and U Mann-Whitney test). Fulv., fulvestrant. Scale bars, 10 μm in (A) and 30 μm in (C–F). n.s., not significant, * $p < 0.05$, ** $p < 0.01$. Error bars represent standard deviation. Arrowheads indicate mammary epithelial cells in extraductal region (D–F). In the graphs, crosses with different colors indicated the values of different samples (B) and animals (C and F).

and Britt, 2017; Kelsey et al., 1993) and a combination of radiation and E2 treatment transformed normal mammary cells *in vitro* (Calaf and Hei, 2000), there is no experimental evidence showing that estrogen receptor α (ER α)-mediated estrogen signaling induces mammary dysplasia from normal mammary epithelial cells *in vivo*.

Estrogen regulates gene expression via the activation of ER α . In mammary glands, ER α is expressed mainly in mammary epithelial cells. Although there are various functional models of ER α action, in the classical mechanism of ER α , estrogen-bound ER α forms a dimer, localizes in the nucleus, and binds to its DNA-binding site to regulate gene expression (reviews Arnal et al., 2017; Burns and Korach, 2012; Heldring et al., 2007; Maggi, 2011; Yaşar et al., 2017). Thus far, various ER α -regulated genes have been identified (Liang and Shang, 2013; Manavathi et al., 2013; Siersbæk et al., 2018); these include *growth regulating estrogen receptor-binding 1* (GREB1), *trefoil factor 1* (TFF1, pS2), and *myelocytomatosis* (MYC) (Barkhem et al., 2002; Lin et al., 2004; Wang et al., 2011). Myc expression is associated with poor survival in breast cancer (Deming et al., 2000; Green et al., 2016). Myc (c-Myc) is also involved in breast cancer proliferation (Hart et al., 2014; Liao and Dickson, 2000; Liao et al., 2000). During ER α -mediated gene regulation, a DNA double-strand break is made at the promoter of a target gene to promote its expression (Ju et al., 2006; Williamson and Lees-Miller, 2011). Whether ER α -mediated gene regulation with a DNA double-strand break is involved in dysplasia formation remains unclear. In this study, we successfully established a novel dysplasia model system and investigated the mechanism of dysplasia formation.

RESULTS**Enhancement of ER α -Mediated Estrogen Signaling Causes Mammary Ductal Dysplasia**

To investigate E2-induced DNA damage *in vitro*, we treated an ER α -positive breast cancer cell line, MCF-7, with or without estradiol (E2), the most active form of estrogen, for 2 h and counted the number of the signals of phosphorylated-histone H2AX (gamma-H2AX, gH2AX), a marker of DNA double-strand breaks (Figure S1A). The number of gH2AX signals was increased by E2 treatment and reduced by cotreatment with fulvestrant, an estrogen receptor inhibitor (Figure S1A), indicating that E2 treatment causes DNA double-strand breaks via its receptor. An inhibitor of DNA-dependent protein kinase (DNA-PK), NU-7441, inhibits non-homologous end joining repair, one of the repair mechanisms of DNA double-strand breaks (Leahy et al., 2004). NU-7441 cotreatment did not change the number of gH2AX signals after 2-h E2 treatment (Figure S1A), indicating that the loss of DNA-PK function does not change E2-generated DNA damage under our conditions.

To determine whether estrogen-induced DNA double-strand breaks are involved in the regulation of the downstream genes of estrogen signaling, we reduced the capacity of non-homologous end joining by knocking down PRKDC, which encodes the catalytic subunit of DNA-PK (Davis et al., 2014). Cells were washed with medium in the absence of E2 after 2-h E2 treatment to analyze repair capacity. No increase in the number of gH2AX signals was observed in control cells (Figure 1A), indicating that cells were allowed to repair E2-induced DNA double-strand breaks during 2 h after washing out E2 under our conditions. However, larger number of the gH2AX signals were observed after washing in PRKDC-knockdown cells than in control cells (Figures 1A and S1B), suggesting that the loss of DNA-PK function delays the repair of E2-induced DNA double-strand breaks. Long-lived DNA breaks (unrepaired at least 12 h after DNA damage induction) are believed to be involved in transcriptional regulation, at least in specific cases (Puc et al., 2017). To investigate the expression of ER α downstream genes under our conditions, mRNA levels were

quantified in cells with or without 6-h E2 treatment (Figure 1B). *PRKDC* knockdown increased *GREB1* expression in untreated cells. In E2-treated groups, the expression of *GREB1* was enhanced following *PRKDC* knockdown. The expression of *TFF1* was not altered by *PRKDC* knockdown. Interestingly, after E2 treatment, we observed 2-fold higher *MYC* expression in *PRKDC*-knockdown cells than in control cells. We treated cells with NU-7441 and L189, an inhibitor for ligases I, III, and IV, to reduce the capacity of non-homologous end joining (Figure S1D). Ligases I, III, and IV are involved in DNA repair including non-homologous end joining. In cells treated with these inhibitors, higher *Myc* expression was observed after E2 stimulation than in DMSO-treated control cells (Figure S1E). These results suggest that a reduction in the repair capacity of DNA double-strand breaks enhances *MYC* expression in response to E2 stimulation.

We injected E2 (6 $\mu\text{g}/\text{mouse}$) intraperitoneally into scid mice with a genetic defect in DNA-PK catalytic subunit function (Bosma et al., 1983; Kirchgessner et al., 1995). The serum concentration of E2 was transiently increased and reduced to the background level after 6 h in both wild-type and scid mice (Figure S1C). The results of gH2AX staining showed an increased number of gH2AX-positive mammary epithelial cells (Figure 1C). As expected, scid mice showed a larger number of gH2AX-positive cells than wild-type mice at 6 h (5-fold larger) and 9 h (3-fold larger) after E2 administration. No increase in the number of gH2AX-positive mammary epithelial cells was observed at 9 h in wild-type and at 12 h in scid mice, suggesting that E2-induced DNA double-strand breaks were repaired at these time points, and E2 administration transiently induced DNA double-strand breaks under our conditions. Increase in the number of gH2AX-positive mammary epithelial cells was not observed in mice administered E2 and fulvestrant.

To investigate whether long-term E2 administration could cause an abnormality in the mammary gland, we performed consecutive daily injections of E2 for 30 days. No significant change in body weights was observed after 30 days of injection (Figure S2A). Hematoxylin and eosin (H&E) staining showed normal mammary ducts in both wild-type and scid mice at day 7 (Figure S2B). At day 30, whereas E2-injected wild-type (WT + E2) and phosphate-buffered saline (PBS)-injected scid (scid + PBS) mice exhibited normal mammary ducts (Figure 1D), dysplasia formation (i.e., increased cell number, loss of the biphasic mammary epithelial and myoepithelial pattern, and epithelial cell expansion to the outside of a duct) was observed in E2-injected scid mice (scid + E2) (Figures 1D and S2C). To examine whether mammary ducts with dysplasia had disrupted basement membrane, we coimmunostained for Laminin, the component of basement membrane, and CK8, the mammary epithelial cell marker. Some mammary ducts with dysplasia showed disrupted basement membrane and mammary epithelial cell invasion (Figure S2D). Because human breast cancer shows disruption in the myoepithelial layer (Cichon et al., 2010), we immunostained cells for the myoepithelial cell markers cytokeratin 5 (CK5) (Figure 1E) and p63 (Figure S2E). We observed a disruption in the myoepithelial layers in mammary ducts with dysplasia. To determine whether mammary epithelial cells of the ducts with dysplasia invaded the outside of the myoepithelial layer, coimmunostaining of CK5 and CK8 was performed (Figure 1F). The results revealed mammary ducts with increased mammary epithelial cell numbers and the loss of the biphasic pattern (Figure 1F intraductal) and mammary ducts with epithelial cells in the extraductal region with a disruption in the CK5 cell layer (Figure 1F extraductal) in scid + E2. As terminal end buds are epithelial cell-rich regions that can be identified as a duct with no fibrous stroma region (Sternlicht, 2006) and as it is difficult to distinguish dysplasia from normal terminal end buds, these were excluded in the analyses. We analyzed the frequency of dysplasia formation and observed significant increases in both intraductal and extraductal expansion (Figure 1F graph, Table S1). A duct with both intraductal and extraductal expansion was counted as a duct with extraductal expansion. These results suggest that repetitive E2 administration induces mammary ductal dysplasia in scid mice. Coadministration with the estrogen receptor inhibitor (scid + E2 + Fulv.) showed no increase in the frequency of dysplasia, suggesting that the suppression of estrogen receptor function may prevent dysplasia formation in a DNA repair-deficient condition. ER α expression was observed in mammary epithelial cells in both normal and dysplastic ducts (Figure S2F). ER α positivity was not only difference between PBS and E2 administration but also between normal and dysplastic ducts in scid mice.

We coadministered NU-7441, a DNA-PK inhibitor, and E2 to two wild-type strains, C.B17/Icr and C57BL/6J. C.B17/Icr is the parental strain of scid mice. C57BL/6J is a commonly used strain. At day 30, we observed an increase in dysplasia formation in NU-7441 + E2 mice compared with NU-7441 + PBS mice in both strains (Figure S3 and Table S1). This result indicates that E2 administration can induce mammary ductal dysplasia not only in scid mice but also in wild-type strains with induced DNA repair defect.




Figure 2. Progesterone Inhibits Estrogen-Induced Mammary Ductal Dysplasia

(A) Progesterone receptor (*PGR*) gene was knocked down ($n = 3$ experiments, Student's *t* test to shScr control).

(B) DNA double-strand breaks were detected by gH2AX immunostaining. Numbers of gH2AX foci per cell were analyzed (jitter plot) ($n = 3$ independent experiments, total 380–520 cells in each group, U Mann-Whitney test).

(C) Typical images of H&E staining are shown. The table shows ratios of dysplasia ($n = 6$ mice [one image from each mouse, total six images], E2 13.96% and E2 + PG 6.69% [$p = 0.038$, versus E2], U Mann-Whitney test).

(D) Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion were quantified ($n = 8$ mice, U Mann-Whitney test).

Scale bars, 10 μ m in (B) and 30 μ m in (C and D). n.s., not significant, * $p < 0.05$, ** $p < 0.01$. Error bars represent standard deviation. Arrowheads indicate mammary epithelial cells in extraductal region (C and D). In the graphs, crosses with different colors indicated the values of different samples (A) and animals (D).

Progesterone Inhibits E2-Induced Dysplasia Formation

Progesterone (PG), a female hormone, alters ER α chromatin binding events in malignant breast cancer through progesterone receptor (PGR), which changes gene expression patterns, and the administration of PG reduced E2-dependent tumor growth in mouse xenograft experiments with MCF-7 cells (Mohammed et al., 2015). To determine whether PG-activated PGR inhibits E2-induced DNA double-strand breaks in MCF-7 cells, we performed a combination treatment of E2 and PG for 4 h with or without *PGR* knockdown (Figures 2A and 2B). The number of gH2AX signals was increased by E2 treatment but not by the combination of E2 and PG (Figure 2B). In *PGR*-knockdown cells, the combination treatment of E2 and PG resulted in increased number of gH2AX signals, similar to E2 treatment, suggesting that PGR prevents E2-induced DNA double-strand breaks.




Figure 3. Estrogen Administration Promotes Mammary Epithelial Cell Proliferation in scid Mice

(A) PCNA-positive mammary epithelial cells were detected at day 30. Ratios of the positive cells were analyzed ($n = 6$ mice in WT + E2 and scid + E2 + Fulv. groups, and $n = 8$ mice in scid + PBS and scid + E2 groups, one-way ANOVA followed by Tukey's test).

(B) Ki-67-positive mammary epithelial cells were detected. Ratios of the positive cells were analyzed ($n = 6$ mice, one-way ANOVA followed by Tukey's test).

(C) PCNA-positive cells were analyzed in day 7 mice ($n = 6$ mice in WT + E2 and scid + E2 groups, and $n = 3$ in scid + PBS group, one-way ANOVA followed by Tukey's test).

Figure 3. Continued

(D) Carmine alum staining was performed in mammary ducts of day 30 mice. Numbers of branches in 9 mm² area close to lymph node were counted ($n = 10$ mice in WT + E2, scid + PBS, and scid + E2 groups, $n = 6$ mice in scid + E2 + Fulv. group, one-way ANOVA followed by Tukey's test). Fulv., fulvestrant.

Scale bars, 30 μ m in (A–C) and 2 mm in (D). * $p < 0.05$, ** $p < 0.01$. Error bars represent standard deviation. In the graphs, crosses with different colors indicated the values of different animals.

The function of PG in dysplasia formation *in vivo* remains elusive. To this end, we coinjected E2 and PG into our dysplasia model system. In scid mice at day 30, the administration of E2 alone caused dysplasia formation, and the coadministration of E2 and PG prevented dysplasia formation (Figure 2C). Double immunostaining for CK5 and CK8 showed that PG administration prevented extraductal expansion (Figure 2D). The quantification of intraductal and extraductal expansion showed that PG reduced the frequencies of these abnormalities (Figure 2D). These results suggest that PG has a protective effect against E2-induced DNA damage and dysplasia formation in a DNA-repair-deficient condition.

Estrogen Promotes Mammary Epithelial Cell Proliferation

As the number of CK8-positive cells was likely increased in scid + E2 mice (Figure 1F), we investigated cell proliferation by immunostaining for proliferating cell nuclear antigen (PCNA), an S-phase marker, and Ki-67, a proliferation marker, at day 30 (Figures 3A and 3B). The results of immunostaining showed that the ratio of proliferating mammary epithelial cells was increased 1.5-fold in scid + E2 mice, and this increase was inhibited by the ER α inhibitor (scid + E2+Fulv.). An increased number of proliferating cells was also observed at day 7 (Figures S4 and 3C). To investigate organ-level changes, we visualized mammary ducts with carmine alum staining at day 30 (Figure 3D). The mammary glands of scid + E2 mice were more densely distributed than those of the control mice and exhibited more small branches. The number of branches was increased in scid + E2 mice compared with control mice (Figure 3D graph). These results suggest that E2 administration induces cell proliferation in the mammary glands of scid mice.

E2-Induced Myc Expression Causes Mammary Ductal Dysplasia

We hypothesized that one of the causes of dysplasia is the E2-induced expression of ER α downstream genes. Our *in vitro* experiments showed that E2 administration has the potential to increase the expression of a protooncogene, MYC (Figure 1B). In a previous study, mice with enhanced Myc expression exhibited mammary cell proliferation and an increase in branching (Tseng et al., 2014), similar to our observation in scid + E2 mice (Figure 3). We therefore focused on Myc. The results of Myc mRNA *in situ* hybridization showed that although Myc mRNA expression was increased at 2 h after E2 injection in the mammary ducts of both wild-type and scid mice, scid mice had stronger signals than did wild-type mice (Figure S5A). In scid mice, Myc mRNA expression was still clearly observed at 6 and 9 h and faintly at 12 and 24 h, whereas the signal was not observed at 6 h onward in wild-type mice (Figure S5A). In the results of gH2AX staining (Figure 1C), the number gH2AX-positive mammary epithelial cells were transiently increased at 6 and 9 h in scid mice. These results suggest that E2-induced double-strand breaks may promote Myc expression, but not elongate Myc expression for longer periods. A significant increase in the number of Myc-positive mammary epithelial cells was observed in scid mice at 6 h and day 30 (Figures 4A and S5B). This increase was not observed following the coadministration of E2 and fulvestrant or PG (Figure 4A). These results indicate that E2 administration increases Myc expression *in vivo*.

To determine whether estrogen signaling promotes MYC expression in human breast cancer, we analyzed the expression of Myc mRNA and ER α protein in a tissue microarray with human breast tissues. Myc mRNA was observed in the cytoplasm, and ER α was localized in the nucleus (Figure 4B). We observed Myc and ER α double-positive cells in the samples of hyperplasia, ductal carcinoma *in situ*, and invasive ductal carcinoma. Because of intratumoral heterogeneity, there were also Myc-positive ER α -negative, Myc-negative ER α -positive, and Myc and ER α double-negative cells. We analyzed the ratio of Myc-positive tissues in ER α -negative and ER α -positive malignant breast cancers, and Myc positivity was higher in ER α -positive tissues than in ER α -negative tissues (Figure 4B graph, negative 43.58% versus positive 93.10%). In Myc-positive ER α -positive tissues, 26 of 27 samples had Myc and ER α double-positive cells (96.29%). These observations suggest that estrogen signaling may be involved in the modulation of Myc expression in human breast cancer.

We coadministered E2 and the Myc inhibitor KJ-Pyr-9 (Hart et al., 2014), in scid mice, to investigate the involvement of Myc in dysplasia formation. We observed around a 2-fold reduction in the ratio of




Figure 4. Estrogen-Induced Myc Expression Promotes Mammary Epithelial Cell Proliferation and Dysplasia Formation

(A) Typical images of Myc immunostaining are shown. Ratios of Myc-positive mammary epithelial cells are analyzed ($n = 6$ mice in WT + E2 and scid + E2, $n = 4$ mice in scid + E2 + Fulv. and scid + E2 + PG, one-way ANOVA followed by Tukey's test). (B) Typical images of the combination of MYC *in situ* hybridization and ER α immunostaining are shown. Arrowheads indicate MYC-expressing ER α -positive cells. MYC positivity was analyzed in the samples from malignant tumors ($n = 39$ ER α -negative and 29 ER α -positive samples, Fisher's exact test). (C) PCNA was detected in mammary glands of mice treated with or without a Myc inhibitor, KJ-Pyr-9. Ratio of PCNA-positive cells were quantified ($n = 6$ mice, Student's t test). (D–F) Typical images of carmine alum staining are shown. Numbers of branches in 9 mm^2 area close to lymph node were counted ($n = 6$ mice, Student's t test). (E) Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion were quantified ($n = 6$ mice, U Mann-Whitney test). Arrowheads indicate mammary

Figure 4. Continued

epithelial cells in extraductal region. (F) E2-induced *Myc* expression causes mammary ductal dysplasia in scid mice. Fulv.: fulvestrant, KJ, KJ-Pyr-9.

Scale bars, 30 μm in (A, C, and E), 10 μm in (B), and 2 mm in (D). * $p < 0.05$, ** $p < 0.01$. Error bars represent standard deviation. In the graphs, crosses with different colors indicated the values of different animals.

PCNA-positive mammary epithelial cells by *Myc* inhibition compared with the DMSO control at day 30 (Figure 4C). At the organ level, the number of branching points was also reduced (Figure 4D). These results indicate that *Myc* inhibition leads to reduced E2-induced cell proliferation in the mammary gland in scid mice.

Ductal dysplasia was investigated with H&E staining and immunostaining for CK5 and CK8 at day 30. Most mammary ducts (96.04%) were normal in the *Myc* inhibitor-administered group (Figure S5C). Moreover, intraductal and extraductal expansion was significantly reduced following administration of the *Myc* inhibitor (Figure 4E). The *Myc* inhibitor did not alter ER α positivity (Figure S5D). These results indicate that E2-induced *Myc* expression is one of the causes of mammary ductal dysplasia (Figure 4F).

Isoflavones Prevent E2-Induced Dysplasia Formation

Our dysplasia model system can be utilized to study breast cancer prevention. Isoflavones are flavonoids and are rich in soybean. Epidemiological studies have suggested that isoflavones have a protective effect against breast cancer (Fritz et al., 2013). Genistein, an isoflavone, inhibited breast cancer cell growth (Shao et al., 1998). On the other hand, a study using breast cancer cells showed that genistein promoted tumor growth (Hsieh et al., 1998). E2 and isoflavones bound to estrogen receptors competitively, and isoflavone binding reduced estrogen receptor-mediated gene expression *in vitro* (Morito et al., 2001). Therefore, the effect of isoflavones in breast cancer is still controversial. To address this issue, we investigated the effect of isoflavones in our dysplasia model system. We used two isoflavones, (S)-equol and genistein. When E2-induced DNA double-strand breaks were analyzed, both isoflavones reduced E2-induced DNA damage (Figure 5A). *MYC* mRNA quantification showed that isoflavones reduced *MYC* expression 1.4-fold under E2-treated conditions compared with treatment with E2 alone, although its expression level was higher than in the PBS control (Figure 5B). These results suggest that isoflavones have the potential to reduce E2 function.

The coadministration of E2 and isoflavones reduced the proliferation of mammary epithelial cells in scid mice at day 30 (Figures 5C and S6A). The number of branches was reduced by isoflavones (Figures 5D and S6B). These results suggest that isoflavones are effective at preventing E2-induced cell proliferation. H&E staining showed that most of the mammary ducts of mice coadministered E2 and isoflavones had normal ductal structures and retained the biphasic mammary epithelial and myoepithelial pattern at day 30 (Figure 5E). The results of CK5 and CK8 immunostaining showed that the ratio of intraductal and extraductal expansion was reduced by isoflavone administration (Figure 5F). These results indicate that isoflavones have the potential to prevent E2-induced dysplasia formation in scid mice.

To investigate whether PG and isoflavones work in the same pathway to prevent dysplasia formation, we performed combination treatments of E2, PG, and isoflavones. In the results of gH2AX staining at 6 h, administration of PG and isoflavones in combination with E2 did not show increase in the number of gH2AX-positive mammary epithelial cells (Figures 5G and S6C). *Myc* positivity was reduced in the mice administered E2 + isoflavones, although the positivity was higher than control at 6 h (Figures 5H and S6D). This observation is consistent with our *in vitro* assays (Figure 5B). E2 + PG administration showed a comparable *Myc* positivity with control (Figure 4A). Combination treatment of E2 + PG + isoflavones also showed a similar *Myc* positivity to the control. These results suggest that although both PG and isoflavones can reduce E2-induced DNA double-strand breaks, the inhibitory mechanism of *Myc* expression was not the same.

Progesterone, *Myc* Inhibitor, and Isoflavones Have a Potential to Prevent Mammary Ductal Dysplasia Formation in Wild-Type Mice

To investigate the effects of PG, KJ-Pyr-9, (S)-equol, and genistein in wild-type mice without DNA repair deficiency, we coadministered E2 and these materials to C57BL/6J mice for 30 days. In the results of CK8 and CK5 double staining (Figure 6), mice administered E2 alone showed slight increase in the




Figure 5. Isoflavones Inhibit Dysplasia Formation by Preventing the Function of Estrogen in scid Mice

(A) DNA double-strand breaks were detected by gH2AX immunostaining. Numbers of gH2AX foci per cell were analyzed (jitter plot) ($n = 3$ independent experiments, total 550–670 cells in each group, U Mann-Whitney test).

(B) MYC mRNA levels were quantified in MCF-7 cells ($n = 3$ experiments, one-way ANOVA followed by Tukey’s test).

(C) Ratios of PCNA-positive cells were analyzed ($n = 6$ mice, one-way ANOVA followed by Tukey’s test).

(D) Numbers of branches were analyzed in carmine alum-stained mammary glands ($n = 6$ mice, one-way ANOVA followed by Tukey’s test).

(E) Typical images of H&E staining are shown. The table shows ratios of dysplasia ($n = 6$ mice [one image from each mouse, total six images], PBS 2.42%, E2 14.90% [$p = 0.002$, versus PBS], E2 + Eq. 3.76% [$p = 0.445$, versus PBS], and E2 + Ge. 4.39% [$p = 0.445$, versus PBS], U Mann-Whitney test).

(F) Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion were quantified ($n = 6$ mice in scid + PBS, scid + E2 + Eq., and scid + E2 + Ge. groups, $n = 5$ mice in scid + E2, one-way ANOVA followed by Tukey’s test and U Mann-Whitney test).

Figure 5. Continued

(G) Ratios of gH2AX-positive mammary epithelial cells were analyzed ($n = 3$ mice, one-way ANOVA followed by Tukey's test).

(H) Ratios of Myc-positive mammary epithelial cells were analyzed ($n = 3$ mice, one-way ANOVA followed by Tukey's test).

Eq, (S)-equol, Ge., genistein.

Scale bars, 10 μm in (A) and 30 μm in (E and F). * $p < 0.05$, ** $p < 0.01$. Error bars represent standard deviation. Arrowheads indicate mammary epithelial cells in extraductal region (E and F). In the graphs, crosses with different colors indicated the values of different samples (B) and animals (C, D, and F–H).

frequencies of intraductal and extraductal expansion, although the changes were not statistically significant between mice administered PBS and E2. This slight increase was prevented by coadministration with PG, KJ-Pyr-9, (S)-equol, and genistein. These results suggest that PG, Myc inhibitor, and isoflavones may have a potential to prevent E2-induced mammary ductal dysplasia.

DISCUSSION

We demonstrated E2-induced mammary ductal dysplasia in mice, providing direct evidence that estrogen causes mammary ductal dysplasia. This study showed that E2 administration in scid mice enhances *Myc* expression, which promotes dysplasia formation. In humans, long-term estrogen exposure has the potential to cause breast cancer (Dall and Britt, 2017; Kelsey et al., 1993). On the other hand, DNA repair capacity is not maintained throughout life (Kalfalah et al., 2015; Li et al., 2016). In the breast, human mammary epithelial cells from aged donors were more sensitive to mammography-induced DNA damage than cells from young donors (Hernández et al., 2013). Mammary epithelial cells from older women showed a delay in DNA double-strand break repair, compared with those from younger women (Anglada et al., 2019). Mutations in genes related to the DNA damage response/repair lead to the risk of developing breast cancer (Miki et al., 1994; Stankovic et al., 1998). Our dysplasia-inducing model system (i.e., 30-day E2 injection in mice with reduced DNA repair capacity) may mimic some of the situations of human breast tissue that are susceptible to mammary ductal dysplasia.

Although our dysplasia model uses an excess amount of E2 and mice with reduced DNA repair capacity, it will be useful to investigate the mechanism of dysplasia formation and to develop a method for dysplasia prevention. By using this system, we revealed that *Myc* is one of the causes of dysplasia formation. However, one question that remains is why does E2 promote *Myc* expression and cell proliferation in almost all parts of a mammary gland but dysplasia occurs in only a small portion. To address this question, the identification of other factors is required, which may be facilitated with our dysplasia model system. Although *Myc* expression alone is not sufficient to develop malignant breast tumors (Stewart et al., 1984; Tseng et al., 2014), given that *Myc* overexpression induces a replicative stress and stress-associated diseases, including cancer (Murga et al., 2011), E2-induced MYC expression may be an early event in breast tumorigenesis. In addition, we showed dysplasia formation in wild-type strains by coadministration of the DNA-PK inhibitor and E2. These results indicate that our dysplasia model system can be utilized in various strains and genetically engineered mouse models, such as *Tp53*-knockout mice.

We observed that the number of DNA double-strand breaks and *Myc* expression were increased in scid mice at 6 and 9 h after E2 administration. DNA double-strand breaks were repaired at 12 h. On the other hand, in scid mice, E2 administration did not immediately promote mammary epithelial cell proliferation, and the proliferation was observed at day 7. These results suggest that E2-induced DNA double-strand breaks and *Myc* expression are not directly involved in the initiation of cell proliferation, or in addition to *Myc* expression, mammary epithelial cell proliferation requires unidentified factor(s), which works at day 7 in our model system.

It is considered that breast cancer metastasizes in a very early stage in some cases (Fisher, 1980; Fisher et al., 1981), which causes distant metastasis and metastatic recurrence. Given that microinvasion is an early event in metastasis, inhibition of microinvasion in a very early stage may reduce breast cancer mortality. E2-induced dysplasia observed in this study showed microinvasion. Administration of *Myc* inhibitor or isoflavones inhibited it. These results suggest that our dysplasia model system can be utilized to study very-early-stage breast cancer for metastasis prevention.

For the breast cancer prevention study, we showed the first experimental evidence that isoflavones inhibited E2-induced dysplasia formation in a DNA repair-deficient condition. Although our dysplasia




Figure 6. Progesterone, Myc Inhibitor, and Isoflavones Have a Potential to Reduce Mammary Dysplasia Formation

C57BL/6J mice were administered E2 in combination with PG, KJ, Eq. or Ge. for 30 days. Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion were quantified ($n = 6$ mice, one-way ANOVA followed by Tukey's test and U Mann-Whitney test). Scale bars, 30 μm . Error bars represent standard deviation. In the graphs, crosses with different colors indicated the values of different animals. Eq., (S)-equol; Ge., genistein; KJ, KJ-Pyr-9.

model system does not mimic all kinds of breast cancer types, our findings suggest that isoflavones can be utilized to prevent breast cancer. In the future, this dysplasia induction model system may contribute to the understanding of breast cancer tumorigenesis and to the development of breast cancer prevention.

Limitation of the Study

Our dysplasia model system is a model for estrogen-induced dysplasia, but not for dysplasia caused by other factors, implying that our findings contribute to the understanding of the tumorigenesis of some breast cancer types, although early stages of most breast cancer types exhibit dysplasia with similar morphological changes.

METHODS

All methods can be found in the accompanying [Transparent Methods supplemental file](#).

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.isci.2020.100821>.

ACKNOWLEDGMENTS

We thank Dr. Makoto Noda, Dr. Yo-ichi Nabeshima, and Mr. Akihiro Nakamura for fruitful discussion. We thank Dr. Shin-ichiro Imai for writing assistance. We thank Dr. Yasuhiko Kawakami for sharing the information about experiments. We thank Ms. Sunao Tanaka, Dr. Noriko Senda, and Ms. Remi Akagawa for technical assistance. We thank Medical Research Support Center and Center for Anatomical, Pathological and Forensic Medical Researches, Graduate School of Medicine, Kyoto University, for technical assistance. Short tandem repeat analysis for cell authentication was performed by BEX Co., Ltd. The manuscript was proofread by *American Journal Experts*. We thank the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa. Financial supports were provided by Taiho Pharmaceutical, Cactus Communications K.K., Sanwa Shurui Co. Ltd., and JSPS KAKENHI Grant Number JP19K07665.

AUTHOR CONTRIBUTIONS

J.I. conceived the work, designed and performed experiments, analyzed and interpreted data, and drafted the manuscript. R.T. designed experiments, analyzed and interpreted data, and revised the manuscript. H.S., M. Tsuda, and S.M. designed experiments. Y.M. and T.I. performed experiments. F.S. and S.T. supervised the work. M. Toi interpreted data.

DECLARATION OF INTERESTS

J.I. was an employee of Kyoto University's Sponsored Research Program funded by Taiho Pharmaceutical. R.T., H.S., M. Tsuda, S.M., Y.M., T.I., F.S., S.T., and M. Toi have no conflict of interest. The funding source had no role in the study design, experiment, analysis, interpretation, or writing the manuscript.

Received: July 18, 2019

Revised: November 13, 2019

Accepted: January 3, 2020

Published: February 21, 2020

REFERENCES

- Anglada, T., Repullés, J., Espinal, A., LaBarge, M.A., Stampfer, M.R., Genescà, A., and Martín, M. (2019). Delayed gammaH2AX foci disappearance in mammary epithelial cells from aged women reveals an age-associated DNA repair defect. *Aging* 11, 1510–1523.
- Arnal, J.F., Lenfant, F., Metivier, R., Flouriot, G., Henrion, D., Adlanmerini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B., et al. (2017). Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. *Physiol. Rev.* 97, 1045–1087.
- Arpino, G., Laucirica, R., and Elledge, R.M. (2005). Premalignant and in situ breast disease: biology and clinical implications. *Ann. Intern. Med.* 143, 446–457.
- Barkhem, T., Haldosén, L.A., Gustafsson, J.A., and Nilsson, S. (2002). Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context. *Mol. Endocrinol.* (Baltimore, Md) 16, 2571–2581.
- Bosma, G.C., Custer, R.P., and Bosma, M.J. (1983). A severe combined immunodeficiency mutation in the mouse. *Nature* 301, 527–530.
- Burns, K.A., and Korach, K.S. (2012). Estrogen receptors and human disease: an update. *Arch. Toxicol.* 86, 1491–1504.
- Calaf, G.M., and Hei, T.K. (2000). Establishment of a radiation- and estrogen-induced breast cancer model. *Carcinogenesis* 21, 769–776.
- Cichon, M.A., Degnim, A.C., Visscher, D.W., and Radisky, D.C. (2010). Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. *J. Mammary Gland Biol. Neoplasia* 15, 389–397.
- Dall, G.V., and Britt, K.L. (2017). Estrogen effects on the mammary gland in early and late life and breast cancer risk. *Front. Oncol.* 7, 110.
- Davis, A.J., Chen, B.P., and Chen, D.J. (2014). DNA-PK: a dynamic enzyme in a versatile DSB repair pathway. *DNA Repair* 17, 21–29.
- Deming, S.L., Nass, S.J., Dickson, R.B., and Trock, B.J. (2000). C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. *Br. J. Cancer* 83, 1688–1695.
- Deroo, B.J., and Korach, K.S. (2006). Estrogen receptors and human disease. *J. Clin. Invest.* 116, 561–570.
- Fisher, B. (1980). Laboratory and clinical research in breast cancer—a personal adventure: the David A. Karnofsky memorial lecture. *Cancer Res.* 40, 3863–3874.
- Fisher, B., Wolmark, N., Bauer, M., Redmond, C., and Gebhardt, M. (1981). The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. *Surg. Gynecol. Obstetrics* 152, 765–772.
- Fritz, H., Seely, D., Flower, G., Skidmore, B., Fernandes, R., Vadeboncoeur, S., Kennedy, D., Cooley, K., Wong, R., Sagar, S., et al. (2013). Soy, red clover, and isoflavones and breast cancer: a systematic review. *PLoS One* 8, e81968.
- Green, A.R., Aleskandarany, M.A., Agarwal, D., Elsheikh, S., Nolan, C.C., Diez-Rodriguez, M., Macmillan, R.D., Ball, G.R., Caldas, C., Madhusudan, S., et al. (2016). MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. *Br. J. Cancer* 114, 917–928.
- Guy, C.T., Cardiff, R.D., and Muller, W.J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol. Cell Biol.* 12, 954–961.
- Hart, J.R., Garner, A.L., Yu, J., Ito, Y., Sun, M., Ueno, L., Rhee, J.K., Baksh, M.M., Stefan, E., Hartl, M., et al. (2014). Inhibitor of MYC identified in a Kröhnke pyridine library. *Proc. Natl. Acad. Sci. U S A* 111, 12556–12561.
- Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Strömn, A., Treuter, E., Warner, M., et al. (2007). Estrogen receptors: how do they signal and what are their targets. *Physiol. Rev.* 87, 905–931.

- Hernández, L., Terradas, M., Martín, M., Feijoo, P., Soler, D., Tusell, L., and Genescà, A. (2013). Increased mammogram-induced DNA damage in mammary epithelial cells aged in vitro. *PLoS One* 8, e63052.
- Hsieh, C.Y., Santell, R.C., Haslam, S.Z., and Helferich, W.G. (1998). Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. *Cancer Res.* 58, 3833–3838.
- Ju, B.G., Lunyak, V.V., Perissi, V., Garcia-Bassets, I., Rose, D.W., Glass, C.K., and Rosenfeld, M.G. (2006). A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. *Science* 312, 1798–1802.
- Kalfalah, F., Seggewiß, S., Walter, R., Tigges, J., Moreno-Villanueva, M., Bürkle, A., Ohse, S., Busch, H., Boerries, M., Hildebrandt, B., et al. (2015). Structural chromosome abnormalities, increased DNA strand breaks and DNA strand break repair deficiency in dermal fibroblasts from old female human donors. *Ageing* 7, 110–122.
- Kelsey, J.L., Gammon, M.D., and John, E.M. (1993). Reproductive factors and breast cancer. *Epidemiologic Rev.* 15, 36–47.
- Kirchgessner, C.U., Patil, C.K., Evans, J.W., Cuomo, C.A., Fried, L.M., Carter, T., Oettinger, M.A., and Brown, J.M. (1995). DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. *Science* 267, 1178–1183.
- Kuperwasser, C., Hurlbut, G.D., Kittrell, F.S., Dickinson, E.S., Laucirica, R., Medina, D., Naber, S.P., and Jerry, D.J. (2000). Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. *Am. J. Pathol.* 157, 2151–2159.
- Leahy, J.J., Golding, B.T., Griffin, R.J., Hardcastle, I.R., Richardson, C., Rigoreau, L., and Smith, G.C. (2004). Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. *Bioorg. Med. Chem. Lett.* 14, 6083–6087.
- Li, Y., Hively, W.P., and Varmus, H.E. (2000). Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. *Oncogene* 19, 1002–1009.
- Li, Z., Zhang, W., Chen, Y., Guo, W., Zhang, J., Tang, H., Xu, Z., Zhang, H., Tao, Y., Wang, F., et al. (2016). Impaired DNA double-strand break repair contributes to the age-associated rise of genomic instability in humans. *Cell Death Differ.* 23, 1765–1777.
- Liang, J., and Shang, Y. (2013). Estrogen and cancer. *Annu. Rev. Physiol.* 75, 225–240.
- Liao, D.J., and Dickson, R.B. (2000). c-Myc in breast cancer. *Endocr. Relat. Cancer* 7, 143–164.
- Liao, D.J., Natarajan, G., Deming, S.L., Jamerson, M.H., Johnson, M., Chepko, G., and Dickson, R.B. (2000). Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. *Oncogene* 19, 1307–1317.
- Lin, C.Y., Ström, A., Vega, V.B., Kong, S.L., Yeo, A.L., Thomsen, J.S., Chan, W.C., Doray, B., Bangarusamy, D.K., Ramasamy, A., et al. (2004). Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. *Genome Biol.* 5, R66.
- Maggi, A. (2011). Liganded and unliganded activation of estrogen receptor and hormone replacement therapies. *Biochim. Biophys. Acta* 1812, 1054–1060.
- Manavathi, B., Dey, O., Gajulapalli, V.N., Bhatia, R.S., Bugide, S., and Kumar, R. (2013). Derailed estrogen signaling and breast cancer: an authentic couple. *Endocr. Rev.* 34, 1–32.
- Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L.M., Ding, W., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266, 66–71.
- Mohammed, H., Russell, I.A., Stark, R., Rueda, O.M., Hickey, T.E., Tarulli, G.A., Serandour, A.A., Birrell, S.N., Bruna, A., Saadi, A., et al. (2015). Progesterone receptor modulates ERalpha action in breast cancer. *Nature* 523, 313–317.
- Moraes, R.C., Zhang, X., Harrington, N., Fung, J.Y., Wu, M.F., Hilsenbeck, S.G., Allred, D.C., and Lewis, M.T. (2007). Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. *Development* 134, 1231–1242.
- Morito, K., Hirose, T., Kinjo, J., Hirakawa, T., Okawa, M., Nohara, T., Ogawa, S., Inoue, S., Muramatsu, M., and Masamune, Y. (2001). Interaction of phytoestrogens with estrogen receptors alpha and beta. *Biol. Pharm. Bull.* 24, 351–356.
- Muller, W.J., Sinn, E., Pattengale, P.K., Wallace, R., and Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. *Cell* 54, 105–115.
- Murga, M., Campaner, S., Lopez-Contreras, A.J., Toledo, L.I., Soria, R., Montana, M.F., Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011). Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. *Nat. Struct. Mol. Biol.* 18, 1331–1335.
- Puc, J., Aggarwal, A.K., and Rosenfeld, M.G. (2017). Physiological functions of programmed DNA breaks in signal-induced transcription. *Nat. Rev. Mol. Cell Biol.* 18, 471–476.
- Sgroi, D.C. (2010). Preinvasive breast cancer. *Annu. Rev. Pathol.* 5, 193–221.
- Shao, Z.M., Alpaugh, M.L., Fontana, J.A., and Barsky, S.H. (1998). Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. *J. Cell Biochem.* 69, 44–54.
- Siersbæk, R., Kumar, S., and Carroll, J.S. (2018). Signaling pathways and steroid receptors modulating estrogen receptor alpha function in breast cancer. *Genes Dev.* 32, 1141–1154.
- Stankovic, T., Kidd, A.M., Sutcliffe, A., McGuire, G.M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A.R., Easton, D.F., Lennox, G.G., et al. (1998). ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. *Am. J. Hum. Genet.* 62, 334–345.
- Sternlicht, M.D. (2006). Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. *Breast Cancer Res.* 8, 201.
- Stewart, T.A., Pattengale, P.K., and Leder, P. (1984). Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. *Cell* 38, 627–637.
- Tseng, Y.Y., Moriarity, B.S., Gong, W., Akiyama, R., Tiwari, A., Kawakami, H., Ronning, P., Reuland, B., Guenther, K., Beadnell, T.C., et al. (2014). PVT1 dependence in cancer with MYC copy-number increase. *Nature* 512, 82–86.
- Turner-Ivey, B., Smith, E.L., Rutkovsky, A.C., Spruill, L.S., Mills, J.N., and Ethier, S.P. (2017). Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3. *Breast Cancer Res. Treat.* 164, 349–358.
- Wang, C., Mayer, J.A., Mazumdar, A., Fertuck, K., Kim, H., Brown, M., and Brown, P.H. (2011). Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. *Mol. Endocrinol. (Baltimore, Md)* 25, 1527–1538.
- Weil, M.M., Kittrell, F.S., Yu, Y., McCarthy, M., Zabriskie, R.C., and Ullrich, R.L. (2001). Radiation induces genomic instability and mammary ductal dysplasia in Atm heterozygous mice. *Oncogene* 20, 4409–4411.
- Williamson, L.M., and Lees-Miller, S.P. (2011). Estrogen receptor alpha-mediated transcription induces cell cycle-dependent DNA double-strand breaks. *Carcinogenesis* 32, 279–285.
- Yaşar, P., Ayaz, G., User, S.D., Güpür, G., and Muyan, M. (2017). Molecular mechanism of estrogen-estrogen receptor signaling. *Reprod. Med. Biol.* 16, 4–20.

Supplemental Information

**Estrogen Induces Mammary Ductal Dysplasia
via the Upregulation of Myc Expression
in a DNA-Repair-Deficient Condition**

**Junji Itou, Rei Takahashi, Hiroyuki Sasanuma, Masataka Tsuda, Suguru
Morimoto, Yoshiaki Matsumoto, Tomoko Ishii, Fumiaki Sato, Shunichi
Takeda, and Masakazu Toi**

Estrogen induces mammary ductal dysplasia via the upregulation of Myc expression in a DNA-repair deficient condition.

Junji Itou, Rei Takahashi, Hiroyuki Sasanuma, Masataka Tsuda, Suguru Morimoto, Yoshiaki Matsumoto, Tomoko Ishii, Fumiaki Sato, Shunichi Takeda, Masakazu Toi

Transparent Methods

Supplemental figures

Figure S1 Estrogen administration induces DNA double-strand breaks. Related to Figure 1

Figure S2 Long-term estrogen administration causes dysplasia. Related to Figure 1

Figure S3 Dysplasia is induced by the combination of E2 administration and DNA-PK pharmacological inhibition. Related to Figure 1

Figure S4 Mammary epithelial cell proliferation is observed at day 7 in the dysplasia model system. Related to Figure 3

Figure S5 Estrogen administration induces Myc expression *in vivo* in mammary epithelial cells. Related to Figure 4

Figure S6 Isoflavones inhibit estrogen-induced cell proliferation in the mammary gland. Related to Figure 5

Supplemental table

Table S1 Frequency of dysplasia formation, related to Figure 1, S3

Transparent Methods

Cell culture

MCF-7 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Short tandem repeat analysis was performed for cell authentication in July 2017 and the result showed no contamination and no alteration. Mycoplasma contamination was checked every 3 months by staining with Hoechst 33342 (Dojindo, 346-07951, Kamimashiki, Japan, 1/500 dilution) and no contamination was observed. Cells were maintained in Roswell Park Memorial Institute 1640 (RPMI-1640) medium containing 10% heat-inactivated fetal bovine serum (FBS), 100 units/mL Penicillin, 100 µg/mL Streptomycin and 1nM β-estradiol (E2) (Sigma, E2758, St. Louis, MO, USA) at 37°C with 5% CO₂. To obtain G1 phase cells For gH2AX staining experiments, cells were starved with phenol-red-free FBS-free RPMI-1640 medium containing 100 units/mL Penicillin and 100 µg/mL Streptomycin for 24 h. E2, progesterone (PG) (Sigma, P8783), (S)-equol (Cayman Chemical, 10010173, Ann Arbor, MI, USA) and genistein (Nagara Science, NH010302, Gifu, Japan) were solved in ethanol, diluted with PBS and added to medium (final concentration: 10 nM). Fulvestrant (Sigma, I4409) was solved with ethanol, diluted with PBS and added to medium (final concentration: 100 nM). NU-7441 (AadooQ Bioscience, A11098, Irvine, CA, USA) was solved in DMSO, diluted with PBS and added to medium (final concentration: 0.5 µM). For mRNA quantification of ERα downstream genes, cells were cultured with phenol-red-free RPMI-1640 medium containing 10% charcoal-stripped FBS, 100 units/mL Penicillin and 100 µg/mL Streptomycin for 48 h, subsequently treated with or without 10 nM E2 for 6 h.

Loss of function study

For short hair-pin RNA (shRNA) expression, a lentiviral vector pLKO.1 (Addgene, 8453, Cambridge, MA, USA) was used. Double-strand DNA oligo with shRNA sequence was cloned into the region between *AgeI* and *EcoRI* sites of the vector. The target sequences were 5'-CCAGTGAAAGTCTGAATCATT-3' (shPRKDC #2), 5'-CCTGAAGTCTTTACAACATAT-3' (shPRKDC #4), 5'-GCTGCTGGAAGACGAAAGTTA-3' (shPGR #1) and 5'-CAATACAGCTTCGAGTCATTA-3' (shPGR #2). Control shRNA was 5'-CCTAAGGTTAAGTCGCCCTCG-3' (shScr).

Lentiviral vector was cotransfected with lentiviral envelope and packaging

plasmids, pMDLg/pRRE (Addgene, 12251), pMD2.G (Addgene, 12259) and pRSV-Rev (Addgene, 12253) at a ratio of 2.5:1.0:0.6:0.5 into Lenti-X 293T cells (Takara, 632180, Kusatsu, Japan). The transfection reagent, FuGENE 6 (Promega, E2691, Madison, WI, USA) was used. Lenti-X 293T cells were maintained with Dulbecco's modified Eagle medium containing 10% FBS, 100 units/mL Penicillin and 100 µg/mL Streptomycin. One day after transfection, medium was changed to the medium for MCF-7 cells and incubated for 24~30 h. Medium containing lentiviral particles was filtered (0.22 µm pore size), added to MCF-7 cell culture with 6 µg/mL polybrene and incubated for 48 h. For drug selection to obtain infectants, cells were treated with 1 µg/mL puromycin for 4 days.

Messenger RNA quantification

Cells were cultured in 6-well plate or 6 cm dish. Cells were rinsed with cold PBS and treated with 300 µL of Trizol reagent (Thermo Fisher Scientific, 15596018, Waltham, MA, USA). Sixty µL of chloroform was added, mixed and stand for 5 min. After centrifugation at 4°C, supernatant was collected and purified with PureLink RNA Micro Kit (Thermo Fisher Scientific, 12183016).

Five hundred ng of total RNA was used for complementary DNA (cDNA) synthesis. SuperScript III reverse transcriptase (Thermo Fisher Scientific, 18080044) was used. Synthesized cDNA was diluted with sterilized MilliQ water (1/10 dilution) for real-time polymerase chain reaction (PCR).

Real-time PCR was performed with a reagent, FastStart Universal SYBR Green Master (Sigma, 04 913 850 001, St. Louis, MO, USA). Signals were detected by StepOnePlus real-time PCR system (Thermo Fisher Scientific, 4376600) with StepOne software ver2.2.2.

Primer sequences were: *EF1A1* (internal control) forward: 5'-AAATGACCCACCAATGGAAGCAGC-3' reverse: 5'-TGAGCCGTGTGGCAATCCAATACA-3', *PRKDC* forward: 5'-CGCCGTGTGAATATAAAGATTGG-3' reverse: 5'-CGTGACTGTTTCAGTACGATTAG-3', *GREB1* forward: 5'-CTGCTGTACCTCTGTGACTCTT-3' reverse: 5'-GTCCTGACAGATGACACACAAC-3', *TFF1* forward: 5'-CCCTGGTCCTGGTGTCCAT-3' reverse: 5'-AGCAGCCCTTATTTGCACACT-3', *MYC* forward: 5'-CTCGGATTCTCTGCTCTCCT-3' reverse: 5'-TCTTCCTCATCTTCTTGTTTCCTC-3', *PGR* forward: 5'-

CACAGCGTTTCTATCAACTTACAA-3'
CCGGGACTGGATAAATGTATTC-3'

reverse:

5'-

Immunostaining in cell culture

Cells were plated onto an 8-well chamber slide (Matsunami glass, SCS-N08, Kishiwada, Japan) with 400 μ L medium, and cultured for 2 days. For fixation, a half of the medium was removed, and 200 μ L of 4% paraformaldehyde (PFA) in PBS was added (final 2% PFA). After 10~15 min fixation at room-temperature, cells were washed with PBS containing 0.05% Tween-20 (PBS-T). Permeabilization was performed with PBS containing 0.1% Triton-X 100 for 15 min at room-temperature. Cells were washed with PBS-T twice. Blocking was performed with 5% goat serum-containing PBS-T for 1 h at room-temperature. Cells were incubated with primary antibody in blocking solution for overnight (15~20 h) at 4°C. Primary antibody was anti-gH2AX antibody (S139) (Cell Signaling Technology, 2577S, Danvers, MA, USA, 1/200 dilution). Cells were washed with PBS-T 3 times and incubated with secondary antibody in blocking solution for 1~2 h at room-temperature. Secondary antibody was goat anti-rabbit IgG antibody conjugated to Alexa Fluor 546 (Life Technologies, A11010, 1/1000 dilution). Cells were washed with PBS twice and counterstained with Hoechst 33342 for 30 min at room-temperature. Cells were washed with PBS, dried and mounted with Fluoromount-G (SouthernBiotech, 0100-01, Birmingham, AL, USA).

Mouse experiments

Female C.B17/Icr wild-type (C.B17/Icr-scidJcl +/+) and scid (C.B17/Icr-scidJcl scid/scid) mice were purchased from CLEA Japan (Tokyo, Japan) (6~8-week-old). Six-week-old female C57BL/6J mice were purchased from Japan SLC (Hamamatsu, Japan). Mice were maintained under specific- pathogen-free condition. Intraperitoneal injection was performed with 30G needle in the morning. Injected reagents were E2 (6 μ g/day), PG (6 μ g/day), Fulvestrant (100 μ g/day), NU-7441 (100 μ g/day), KJ-Pyr-9 (Namiki Shoji, HY-19735, Tokyo, Japan, 0.2 mg/day), (S)-equol (6 μ g/day) and genistein (6 μ g/day). Mice were euthanized by cervical dislocation, and mammary glands were isolated. For 30-day samples, mammary glands were isolated at 24 h after final injection. For measurement of E2 serum concentration after administration, 5-week-old female mice were ovariectomized to eliminate endogenous E2. After 5 weeks, E2 was injected

intraperitoneally, and blood samples were collected from tail vein. E2 concentration was measured by using E2 ELISA(EIA) kit (Calbiotech, ES180S-100, El Cajon, CA, USA), SPECTRA max 340PC (Molecular devices, San Jose, CA, USA) and SoftMax Pro 5.4 (Molecular Devices). The animal experiments were approved by the Animal Research Committee of Kyoto University, number MedKyo17554 and MedKyo18321. All animals were maintained according to the Guide for the Care and Use of Laboratory Animals (National Institute of Health Publication).

Immunostaining in mammary gland

For cryo-section, isolated mammary gland was fixed with 4% PFA in PBS shortly (4 °C, 15 min, rocking). the sample was washed with PBS 3 times and incubated with 30% sucrose in PBS for 1~2 h at room-temperature. the sample was embedded in OCT compound (Sakura Finetek, 4583, Tokyo, Japan), and frozen with liquid nitrogen. Ten µm cryo-section was cut at -50°C, and dried. Dried section was fixed with 4% PFA for 3 min at room-temperature and rinsed with PBS. For paraffin-section, mammary gland was fixed with 10% formaldehyde neutral buffer solution for longer than 24 h at room-temperature, dehydrated and embedded in paraffin. Three µm paraffin-section was deparaffinized, washed with PBS and rinsed with H₂O. For heat-induced epitope retrieval, specimen was put into boiling sodium citrate buffer (10 mM sodium citrate, 0.05 % Tween-20, pH 6.0), incubated for 40 min and cooled for 20 min.

Specimen was washed with PBS-T 3 times and blocked with blocking solution (5% goat serum in PBS-T) for 1 h at room-temperature. Specimen was incubated with primary antibody in blocking solution for overnight (15~20 h) at 4 °C. Primary antibodies were anti-gH2AX antibody (Cell Signaling Technology, 2577S, 1/200 dilution), anti-CK8 antibody (Developmental Studies Hybridoma Bank, TROMA-I, Iowa City, IA, USA 1/200 dilution), anti-CK5 antibody (Abcam, ab75869, 1/200 dilution), anti-Laminin antibody (Sigma, L9393, 1/500 dilution), anti-PCNA antibody clone PC10 conjugated to Alexa Fluor 647 (BioLegend, 307912, San Diego, CA, 1/20 dilution), anti-Ki-67 antibody D3B5 (Cell Signaling Technology, 12202S, 1/400 dilution), anti-c-Myc antibody (Abcam, ab32072, 1/200 dilution), anti-ER α antibody (Millipore, 06-935, 1/400 dilution) and anti-ER α antibody SP1 (NeoMarkers, RM-9101-S0, Fremont, CA, USA, 1/100 dilution). Specimen was washed 3 times with PBS-T and incubated with secondary antibody in blocking solution. Secondary antibodies were biotinylated goat anti-rabbit IgG (Vector,

BA-1000, Burlingame, CA, USA, 1/200 dilution), goat anti-rat IgG conjugated to Alexa Fluor 488 (Cell Signaling Technology, 4416S, 1/1000 dilution) and goat anti-rabbit IgG antibody conjugated to Alexa Fluor 546 (Life Technologies, A11010, 1/1000 dilution).

For DAB colorimetric detection, after secondary antibody reaction, specimen was blocked with 3% H₂O₂ for 10 min, washed with PBS 3 times and incubated with ABC kit (Vector, PK-6101). Specimen was washed with PBS and rinsed with H₂O. After DAB reaction, the specimen was washed with H₂O and counterstained with hematoxylin. The specimen was rinsed with H₂O and washed with H₂O for 10 min. Dehydrated specimen was mounted with Malinol (Muto Pure Chemicals, 2009-1, Tokyo, Japan).

For immunofluorescence, after secondary antibody reaction, specimen was washed with PBS twice and counterstained with Hoechst 33342 for 30 min at room-temperature. The specimen was washed with PBS, dried and mounted with Fluoromount-G. In each animal, 3 or 4 sections were analyzed.

Carminium Alum-staining

Isolated mammary gland was fixed with 4% PFA for 2 h at 4°C, washed with PBS twice and washed with H₂O. The sample was incubated with Carminium Alum staining solution (2 mg/mL carminium, 5 mg/mL aluminum potassium sulfate, a small amount of thymol) for overnight (20~24 h) at room-temperature. After staining, the sample was washed with 70% ethanol for 1 h at room-temperature, 95% ethanol for 1 h at room-temperature and 100% ethanol for 1 h at room-temperature. Subsequently the sample was cleared with xylene overnight (16~20 h) at room-temperature. Xylene was replaced to methyl salicylate for storage. One image was taken in each animal and numbers of branches in 9 mm² area close to lymph node were counted.

In situ hybridization

For probe synthesis, DIG RNA labeling kit (SP6/T7) (Roche, 11 175 025 910, Mannheim, Germany) was used. The kit contains a vector, pSPT18, and RNA polymerases. A probe for mouse *Myc* mRNA was used (Itou et al., 2012). The coding sequence of human *MYC* gene was amplified from the cDNA sample of MCF-7 cells. *Myc* and *MYC* genes were cloned into the region between the *Hind*III and the *Eco*RI sites of the pSPT18 vector. Linearized *Myc* and *MYC* vectors were obtained by cutting with *Hind*III and *Pst*I, respectively. T7 RNA polymerase was used. Synthesized RNA probe was purified and

diluted with hybridization solution (50% formamide, 5x SSC, 5x Denharts, 250 µg/mL yeast tRNA, 500 µg/mL salmon sperm DNA).

For cryo-section, section 18 µm thick was dried overnight. A 4 µm thick paraffin-section of the tissue microarray of human breast tissues obtained with patient's informed consent (US Biomax, BRC1502, Derwood, MD, USA) was purchased and deparaffinized. Investigations were performed according to the principles expressed in the Declaration of Helsinki.

Section was fixed with 4% PFA in PBS for 10 min at room-temperature and washed with PBS for 3 min 3 times. The section was treated with 2 µg/mL proteinase K in PBS for 10 min at room-temperature and fixed with 4% PFA in PBS for 5 min at room-temperature. The section was washed with PBS for 3 min 3 times. For acetylation, the section was put into a solution (295 mL H₂O, 4 mL triethanolamine and 0.525 mL HCl), then 0.75 mL acetic anhydride was added, and mixed by dipping. After 10 min acetylation at room-temperature, the section was washed with PBS for 3 min 3 times. PBS was removed, and the section was incubated with hybridization solution for 1 h at room-temperature. Probe solution (30 ng probe in 100 µL hybridization solution) was prepared, heated at 80°C for 5 min, and iced. Hybridization was performed for overnight (18~20 h) at 68°C.

After hybridization, the section was washed with 5x SSC for 10 min at 65°C. Subsequently the section was washed with 0.2x SSC for 1 h at 65°C 3 times, washed with 0.2x SSC for 5 min at room-temperature and washed with TBS solution (0.1M Tris-HCl pH7.5, 0.15M NaCl) for 5 min at room-temperature. Blocking was performed with a blocking solution, 10% goat serum in TBS, for 1 h at room-temperature. After blocking, anti-DIG antibody conjugated to alkaline phosphatase (Roche, 11 093 274 910, 1/5000 dilution) or anti-DIG antibody conjugated to Fluorescein (Roche, 11 207 741 910, 1/200 dilution) was diluted in TBS solution containing 1% goat serum, and the section was incubated with the antibody solution at 4°C for overnight (18~22 h). For combination with immunostaining, a primary antibody was added to the antibody solution.

For alkaline phosphatase colorimetric reaction, section was washed with TBS solution for 5 min at room-temperature 3 times. The section was equilibrated with a solution (0.1M Tris-HCl pH9.5, 0.1M NaCl, 0.05M MgCl₂). Color development was performed with NBT/BCIP solution (Roche, 11 681 451 001) for 4~8 h at room-temperature. Reaction was stopped by washing with PBS. The section was fixed with 4%

PFA in PBS for 20 min at room-temperature. The section was washed with H₂O, dried and mounted with MX oil (Matsunami glass, FX00100). In mouse experiments, 3 or 4 sections were analyzed in each animal.

For combination with *in situ* hybridization and immunostaining, after primary antibody reaction, the section was washed with PBS-T for 5 min 3 times. Incubated with secondary antibodies in 5% goat serum-containing PBS-T. Secondary antibody for *in situ* hybridization was anti-fluorescein/Oregon Green antibody conjugated to Alexa Fluor 488 (Life technologies, A11096, 1/1000 dilution). The section was washed with PBS twice and counterstained with Hoechst 33342 for 30 min at room-temperature. The section was washed with PBS, dried and mounted with Fluoromount-G.

Microscopy

Images of H&E staining, immunostaining and *in situ* hybridization were collected at room temperature with an all-in-one microscope BZ-9000 (Keyence, Osaka, Japan) equipped with a 20x plan apochromatic objective lens (NA: 0.75), a x40 plan apochromatic lens (NA: 0.95) and a x100 plan apochromatic lens (NA: 1.40), and BZ-II Viewer software (Keyence). Hoechst 33342 signal was excited by 340-380 nm light and detected with 435-485 nm light. Alexa Fluor 488 signal was excited by 450-490 nm light and detected with 510-560 nm light. Alexa Fluor 546 signal was excited by 527.5-552.5 nm light and detected with 577.5-632.5 nm light. Alexa Fluor 647 signal was excited by 590-650 nm light and detected with 662.5-737.5 nm light.

Images of Carmine Alum-stained mammary glands were collected at room-temperature with a stereoscope, SMZ800 (Nikon, Tokyo, Japan) and Digital Sight DS-Fi1 (Nikon)

Statistical analyses

Numbers of gH2AX foci of cultured cells were counted manually and analyzed by U Mann-Whitney test. Delta Ct values of real-time PCR experiments were normalized by the mean values of the control groups and analyzed by student's *t*-test and one-way ANOVA followed by Tukey's test. Numbers of mammary epithelial cells having more than 5 gH2AX foci were counted manually and analyzed by one-way ANOVA followed by Tukey's test. Values of E2 serum concentration were normalized by the mean values of 0 h samples and analyze by student's *t*-test between wild-type and scid mice in each

time point. Numbers of mammary ducts with intraductal and extraductal expansion were analyzed by one-way ANOVA followed by Tukey's test and U Mann-Whitney test. Numbers of mammary epithelial cells having immunostaining signals of PCNA, Ki-67, Myc and ER α were counted manually, and analyzed by one-way ANOVA followed by Tukey's test and student's *t*-test. Numbers of branches were analyzed by one-way ANOVA followed by Tukey's test and student's *t*-test. *MYC* positivity of ER α negative and positive groups in the tissue microarray was analyzed by Fisher's exact test. *P* values are listed in Table S2. *P*<0.05 was considered to be statistically significant.

Supplemental reference

Itou, J., Kawakami, H., Quach, T., Osterwalder, M., Evans, S.M., Zeller, R., and Kawakami, Y. (2012). *Islet1* regulates establishment of the posterior hindlimb field upstream of the *Hand2*-*Shh* morphoregulatory gene network in mouse embryos. *Development (Cambridge, England)* *139*, 1620-1629.

Key resource table

Reagent or resource	Source	Identifier
Antibodies		
gH2AX	Cell Signaling Technology	2577S
CK8	Developmental Studies Hybridoma Bank	TROMA-I
CK5	Abcam	ab75869
Laminin	Sigma	L9393
PCNA	BioLegend	307912
Ki-67	Cell Signaling Technology	12202S
c-Myc	Abcam	ab32072
ER α	Millipore	06-935
ER α	NeoMarkers	RM-9101-S0
Biological Samples		
Human breast tissue microarray	US Biomax	BRC1502
Chemicals, Peptides, and Recombinant Proteins		
Hoechst 33342	Dojindo	346-07951

β-estradiol	Sigma	E2758
Progesterone	Sigma	P8783
(S)-equol	Cayman Chemical	10010173
Genistein	Nagara Science	NH010302
Fulvestrant	Sigma	I4409
NU-7441	AdooQ Bioscience	A11098
L189	Cayman Chemical	18374
KJ-Pyr-9	Namiki Shoji	HY-19735
Critical Commercial Assays		
FuGENE 6	Promega	E2691
Trizol	Thermo Fisher Scientific	15596018
PureLink RNA Micro Kit	Thermo Fisher Scientific	12183016
SuperScript III	Thermo Fisher Scientific	18080044
FastStart Universal SYBR Green Master	Sigma	04 913 850 001
E2 ELISA(EIA) kit	Calbiotech	ES180S-100
DIG RNA labeling kit	Roche	11 175 025 910
Experimental models: Cell lines		
MCF-7	ATCC	HTB-22
Lenti-X 293T	Takara	632180
Experimental models: Organisms/Strains		
Mouse: C.B17/Icr-scidJcl +/+	CLEA Japan	N/A
Mouse: C.B17/Icr-scidJcl scid/scid	CLEA Japan	N/A
Mouse: C57BL/6J	Japan SLC	N/A
Oligonucleotides		
Primer: <i>EF1A1</i> forward AAATGACCCACCAATGGAAGCAGC	This paper	N/A
Primer: <i>EF1A1</i> reverse TGAGCCGTGTGGCAATCCAATACA	This paper	N/A
Primer: <i>PRKDC</i> forward CGCCGTGTGAATATAAAGATTGG	This paper	N/A
Primer: <i>PRKDC</i> reverse CGTGACTGTTTCAGTACGATTAG	This paper	N/A

Primer: <i>GREB1</i> forward CTGCTGTACCTCTGTGACTCTT	This paper	N/A
Primer: <i>GREB1</i> reverse GTCCTGACAGATGACACACAAC	This paper	N/A
Primer: <i>TFF1</i> forward CCCTGGTCCTGGTGTCCAT	This paper	N/A
Primer: <i>TFF1</i> reverse AGCAGCCCTTATTTGCACACT	This paper	N/A
Primer: <i>MYC</i> forward CTCGGATTCTCTGCTCTCCT	This paper	N/A
Primer: <i>MYC</i> reverse TCTTCCTCATCTTCTTGTTCCCTC	This paper	N/A
Primer: <i>PGR</i> forward CACAGCGTTTCTATCAACTTACAA	This paper	N/A
Primer: <i>PGR</i> reverse CCGGGACTGGATAAATGTATTC	This paper	N/A
Recombinant DNA		
Plasmid: pLKO.1	Addgene	8453
Plasmid: pMDLg/pRRE	Addgene	12251
Plasmid: pMD2.G	Addgene	12259
Plasmid: pRSV-Rev	Addgene	12253
Software and Algorithms		
ImageJ	NIH	https://imagej.nih.gov/ij/
R	R Development Core Team	https://cran.r-project.org/
JMP	JMP Inc.	Ver 14.0.0




Figure S1 Estrogen administration induces DNA double-strand breaks. Related to Figure 1

A, DNA double-strand breaks were detected in MCF-7 cells. Numbers of gH2AX foci per cell were graphed (jitter plot). Black dots indicate mean values (total 459~760 cells in each group, U Mann-Whitney test). Fulv.: fulvestrant, an estrogen receptor inhibitor.

NU-7441, a DNA-PK inhibitor. B, *PRKDC* gene was knocked-down ($n=3$ experiments, student's *t*-test to shScr control). MCF-7 cells were used. C, E2 serum concentration was measured ($n=3$ mice, student's *t*-test in each time point). D. Numbers of gH2AX foci per cell were graphed (jitter plot). Black dots indicate mean values (total 374~515 cells in each group, U Mann-Whitney test). Messenger RNA levels of *GREB1*, *TFF1* and *MYC* were quantified ($n=3$ experiments, one-way ANOVA followed by Tukey's test). n.s.: not significant, **: $P<0.01$. Error bars represent standard deviation. In the graphs, crosses with different colors indicated the values of different samples.




Figure S2 Long-term estrogen administration causes dysplasia. Related to Figure 1 A, Body weight was measured at day 30 ($n=10$ mice, student's t -test). B, Images of H&E staining of mammary glands are shown. Mammary glands were isolated at day 7. The table shows ratios of dysplasia ($n=6$ mice (one image from each mouse, total 6 images), WT+E2 1.67% and scid+E2 2.60% ($P=0.545$ (vs WT+E2)), U Mann-Whitney test). C,

Additional to Fig. 1D, H&E images of mammary glands of E2-administered scid mice are shown. Arrowheads indicate mammary epithelial cells in extraductal region. D, Basement membrane was stained with anti-Laminin antibody. Arrowheads indicate a region lost basement membrane. E, The myoepithelial marker, p63, was stained. Arrowheads indicate a region lost myoepithelial cells. F, ER α was immunostained. Ratios of ER α -positive mammary epithelial cells were analyzed ($n=3$ mice, one-way ANOVA followed by Tukey's test). Scale bars indicate 30 μm . n.s.: not significant. Error bars represent standard deviation. In the graphs, crosses with different colors indicated the values of different animals.




Figure S3 Dysplasia is induced by the combination of E2 administration and DNA-PK pharmacological inhibition. Related to Figure 1

Fluorescent images of CK8 and CK5 staining are shown. A DNA-PK inhibitor, NU-7441, was administered to wild-type strains, C.B-17/Icr and C57BL/6J, in combination with or without E2. Mammary ducts with intraductal and extraductal expansion were quantified ($n=8$ mice, U Mann-Whitney test in each strain). Arrowheads indicate mammary epithelial cells in extraductal region. Scale bars indicate 30 μm . *: $P<0.05$, **: $P<0.01$. Error bars represent standard deviation. In the graphs, crosses with different colors indicated the values of different animals.




Figure S4 Mammary epithelial cell proliferation is observed at day 7 in the dysplasia model system. Related to Figure 3

Ki-67 was stained at 0 h, 12 h 24 h, 5 days and 7 days. Ratios of Ki-67-positive mammary epithelial cells were analyzed ($n=3$ mice, one-way ANOVA followed by Tukey's test). Scale bars indicate 30 μm . **: $P<0.01$. Error bars represent standard deviation. In the graph, crosses with different colors indicated the values of different animals.




Figure S5 Estrogen administration induces Myc expression *in vivo* in mammary epithelial cells. Related to Figure 4

A, Myc mRNA expression was detected by *in situ* hybridization. Arrowheads indicate Myc-expressing domains. B, Myc expression was detected at day 30. Ratios of Myc-positive mammary epithelial cells were analyzed ($n=3$ mice, one-way ANOVA followed by Tukey's test). C, Typical images of H&E staining are shown. Arrowheads indicate mammary epithelial cells in extraductal region. The table shows ratios of dysplasia ($n=6$ mice (one image from each mouse, total 6 images), E2+DMSO 11.38% and E2+KJ 3.96% ($P=0.623$ (vs E2+DMSO)), U Mann-Whitney test). D, ER α expression was detected at day 30. Ratios of ER α -positive mammary epithelial cells are analyzed ($n=3$ mice, student's *t*-test). KJ: KJ-Pyr-9. Scale bars indicate 30 μ m (A-D). n.s.: not significant, **: $P<0.01$. Error bars represent standard deviation. In the graphs, crosses with different colors indicated the values of different animals.




Figure S6 Isoflavones inhibit estrogen-induced cell proliferation in the mammary gland. Related to Figure 5

A, Typical images of PCNA staining are shown. Quantification is shown in Fig. 5C. B, Typical images of Carmine Alum-staining are shown. Numbers of branching are graphed in Fig. 5D. C, Gamma-H2AX was stained. Ratios of gH2AX-positive mammary epithelial cells are graphed in Fig. 5G. D, Myc immunostaining was performed. Ratios of Myc-positive mammary epithelial cells are shown in Fig. 5H. Eq.: (S)-equol, Ge.: genistein. Scale bars indicate 30 μ m (A, C, D) and 2 mm (B).

Table S1 Frequency of dysplasia formation, related to Figure 1, S3

Mouse	No of mice	Total no of mammary ducts analyzed	intraductal expansion (mean(%) ±S.D.)	extraductal expansion (mean(%) ±S.D.)
C.B-17/Icr WT+E2 30d	10	232	9.68±7.53	0.34±1.09
C.B-17/Icr Scid+PBS 30d	10	235	9.48±6.89	1.14±1.85
C.B-17/Icr Scid+E2 30d	10	283	20.65±9.99	5.92±3.80
C.B-17/Icr WT+NU+PBS 30d	8	204	9.91±6.02	1.12±2.10
C.B-17/Icr WT+NU+E2 30d	8	201	20.35±9.37	6.99±4.87
C57BL/6J+NU+PBS 30d	8	128	8.40±7.62	0.83±2.35
C57BL/6J+NU+E2 30d	8	116	21.76±9.29	8.55±6.48

NU: NU-7441 (DNA-PK inhibitor)